Patent intelligence · US
US 11135283
Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
Patent details — US 11135283
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 5, 2021
- Expiration
- Sep 30, 2041
- Applicant
- IMMUNE DESIGN CORP.
- Claims
- 20
- CPC classes
- A61K, A61K39/21, A61P, A61P31/12
Quick answer
US 11135283 (Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids) is held by IMMUNE DESIGN CORP.. Status: granted. Granted Oct 5, 2021. Expires Sep 30, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IMMUNE DESIGN CORP.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K39/21, A61P, A61P31/12
More from IMMUNE DESIGN CORP.
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 11135283?
US 11135283 (Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids) is held by IMMUNE DESIGN CORP.. Status: granted. Granted Oct 5, 2021. Expires Sep 30, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11135283?
IMMUNE DESIGN CORP. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 11135283 expire?
Our index shows an expiration date of Sep 30, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.